Rain Oncology
Rain Oncology develops innovative, targeted therapies to help patients with cancer get their life back. The company focuses on cancers where genetic identification can predict benefit from treatment, particularly targeting MDM2-dependent, TP53 wildtype cancers. With a mission to help cancer patients live life to the fullest, Rain Oncology leverages industry-leading scientific insight into cancer mechanisms to find precision therapeutic strategies. Founded in 2017, it emphasizes biomarker-based trial designs for rapid decision-making and resource efficiency.
Industries
Nr. of Employees
medium (51-250)
Rain Oncology
8000 Jarvis Ave Suite 204, Newark, CA, 94560
Products
Orally dosed clinical-stage small-molecule MDM2 inhibitor
A clinical-stage oral small molecule designed to inhibit the MDM2–p53 interaction, developed for treatment of tumors dependent on MDM2 with retained wild-type TP53; evaluated across early-phase, basket, and randomized registrational studies.
Orally dosed clinical-stage small-molecule MDM2 inhibitor
A clinical-stage oral small molecule designed to inhibit the MDM2–p53 interaction, developed for treatment of tumors dependent on MDM2 with retained wild-type TP53; evaluated across early-phase, basket, and randomized registrational studies.
Services
Design and execution of multicenter, biomarker-enriched oncology trials, including registrational Phase 3 studies and basket designs with centralized genomic eligibility assessment.
Execution of preclinical programs to characterize pharmacology, biomarker relationships, and combination strategies that inform clinical development decisions.
Design and execution of multicenter, biomarker-enriched oncology trials, including registrational Phase 3 studies and basket designs with centralized genomic eligibility assessment.
Execution of preclinical programs to characterize pharmacology, biomarker relationships, and combination strategies that inform clinical development decisions.
Expertise Areas
- Biomarker-driven oncology clinical trial design and patient selection
- Small-molecule oncology drug discovery and clinical development
- Translational pharmacology and preclinical tumor model evaluation
- Multicenter clinical trial operations and site coordination
Key Technologies
- Small-molecule MDM2–p53 inhibition
- Biomarker-driven patient selection
- Next-generation sequencing-based tumor genomic assays
- Radiographic response assessment using RECIST criteria
News & Updates
Rain Oncology announced it will report financial results for the second quarter of 2023 and provide a corporate update on August 10, 2023.
Results from the Phase 3 MANTRA trial evaluating Milademetan in liposarcoma patients were announced on May 22, 2023.
Financial results and recent progress update for the first quarter of 2023 were provided on May 11, 2023.
Rain Oncology is scheduled to present at the Oppenheimer 33rd Annual Healthcare Conference on March 13, 2023.
Participation in the 2023 Citi Virtual Oncology Leadership Summit was announced for February 21, 2023.
Scheduled participation at the 2023 Guggenheim Healthcare Talks Oncology Day Conference on February 9, 2023.
Rain Oncology announced it will report financial results for the second quarter of 2023 and provide a corporate update on August 10, 2023.
Results from the Phase 3 MANTRA trial evaluating Milademetan in liposarcoma patients were announced on May 22, 2023.
Financial results and recent progress update for the first quarter of 2023 were provided on May 11, 2023.
Rain Oncology is scheduled to present at the Oppenheimer 33rd Annual Healthcare Conference on March 13, 2023.
Participation in the 2023 Citi Virtual Oncology Leadership Summit was announced for February 21, 2023.
Scheduled participation at the 2023 Guggenheim Healthcare Talks Oncology Day Conference on February 9, 2023.